News | December 06, 2011

Buffalo Heart Group Investigates AngelMed's Early Heart Attack Detector

December 6, 2011 — Kaleida Health, part of the Buffalo Heart Group in Buffalo, N.Y., announced its first implant of the AngelMed Guardian cardiac monitor and alert system Nov. 29. The system is designed to reduce the time it takes patients to get to the emergency room during an impending heart attack. Hashmat Ashraf, M.D., performed the first implant in the state of New York, and is among the first physicians across the United States to implant the experimental device.

The system is designed to track significant changes in the heart's electrical signal and then alert patients to seek medical attention.  The objective of the ALERTS Pivotal Study is to assess the system’s safety and effectiveness.

David Garland, a seventh grade teacher at JFK in Buffalo, is the first patient in New York enrolled in the ALERTS study to receive the Guardian system. David had a heart attack in July and underwent stent placement. He has a strong family history of heart disease; his symptoms included fatigue and "indigestion like" pain and had symptoms for weeks before his heart attack.

He was successfully implanted with the device by Ashraf at Kaleida Health Millard Fillmore Gates Hospital.

The ALERTS principal investigator said, "This study provides an excellent opportunity for some of our patients who are at high-risk of having another heart attack. The device is designed to measure changes in the electrical signal of the heart and alert the patient at the earliest onset of a heart attack so that they can get treatment as soon as possible."

According to the American Heart Association, one of every five deaths in the U.S. is attributable to coronary heart disease. Furthermore, 50 percent of heart-attack fatalities occur within one hour of symptom onset, before the patient even reaches the hospital.

The AngelMed Guardian System is comprised of an internal implantable device about the size of a standard pacemaker; it also features a lead into the heart, an external telemetry device, and a programmer that aids physicians in evaluating heart signals.

Buffalo Heart Group is among the first medical facilities to participate in the system trial. To participate in the ALERTS study, patients must meet various inclusion criteria.

For more information: www.angel-med.com

Related Content

Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
TherOx Gains FDA PMA Approval for SSO2 Therapy System
Technology | Cath Lab| September 29, 2017
September 29, 2017 — TherOx Inc. announced that the U.S.
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices| September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
Videos | Chronic Total Occlusion (CTO)| September 28, 2017
Farouc Jaffer, M.D., Ph.D., director of coronary interventions at Massachusetts General Hospital, discusses the newes
Overlay Init